US Residents Only

The Power to Do More

Faced with Hutchinson-Gilford Progeria Syndrome (Progeria) or processing-deficient Progeroid Laminopathies (PDPL)? Know Zokinvy® is the first and only disease-modifying treatment for these ultra-rare diseases.1,2

Prescribe Now

Michiel, 21 and Amber, 13, Belgium. Photo courtesy of The Progeria Research Foundation.

Zokinvy targets a key step in the disease pathophysiology for Progeria and PDPL1,2

See How
Progeria patient playing piano
Sentynl Cares | Zokinvy representative

Starting and staying on Zokinvy matters

Sentynl Cares | Zokinvy provides patients and caregivers with a dedicated, personalized support team to help with insurance coverage investigation, financial support options, and connecting with the pharmacy that dispenses Zokinvy.

Learn More

References:

  • 1. ZOKINVY [prescribing information]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=956a142f-35d6-4fe3-8aef-7e4878d275ed. 2. Gordon LB, Shappell H, Massaro J, et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford Progeria syndrome. JAMA. 2018;319(16):1687-1695.
person with PDPL riding bicycle

INDICATION AND USAGE

ZOKINVY® is indicated in adult and pediatric patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above:

  • To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS)
  • For the treatment of processing-deficient

IMPORTANT SAFETY INFORMATION

Contraindications

ZOKINVY is contraindicated in patients taking:

  • Strong CYP3A inhibitors
  • Strong or moderate CYP3A inducers
  • Midazolam
  • Lovastatin, simvastatin, or atorvastatin
+